WebIntroduction: Prostate cancer is a leading global cause of increased mortality and morbidity in men which can be complicated by castrate-resistant prostate cancer (CRPC). Pharmacological therapy... WebOct 1, 2024 · In detail, approximately 95% of patients in the enzalutamide arm had varying severity of AEs such as decreased appetite, weight loss, and fatigue [ 9 ]. Among such AEs, fatigue is the most frequent, with an incidence of 35.6% and 21.4% in the overall population and the Japanese subgroup of the PREVAIL trial, respectively [ 4, 9 ].
Characterising the castration-resistant prostate cancer
WebMay 20, 2024 · The present study used a retrospective, observational cohort of men with CRPC identified in SEER-Medicare data that was used previously to estimate incidence rates of second primary malignancies ... WebJul 9, 2024 · The incidence rate in patients with no history of SRE was 3.33 (95% CI 3.01-3.68) per 100 person-months, and in patients who had such a history, it was 4.20 (95% CI … rawhide helmet parcel
Metastatic Castration-resistant Prostate Cancer - Medscape
WebNov 1, 2024 · Castration-resistant prostate cancer (CRPC) occurs when prostate cancer (CaP) progresses under therapy-induced castrate conditions. Several mechanisms have … WebAug 6, 2024 · A total of 532 eligible patients were identified with a median age of 73 years (range: 44-97 years). BMAs were prescribed in 232 men (46%), 183 of whom received denosumab. Patients receiving first-line docetaxel for CRPC were more likely to commence BMAs than those receiving abiraterone or enzalutamide (51% vs 31% vs 38%; p = 0.004). WebIn clinical trials, the newest drugs for nmCRPC can delay the spread of prostate cancer for an average of up to nearly 3 1/2 years. People who took these drugs lived up to an … simplee saving account